{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:42:07Z","timestamp":1788284527113,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011827","name":"Guangxi Medical University","doi-asserted-by":"publisher","award":["GXMULJZ202403"],"award-info":[{"award-number":["GXMULJZ202403"]}],"id":[{"id":"10.13039\/501100011827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017691","name":"Guangxi Key Research and Development Program","doi-asserted-by":"publisher","award":["GuiKe AB25069099"],"award-info":[{"award-number":["GuiKe AB25069099"]}],"id":[{"id":"10.13039\/501100017691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017691","name":"Guangxi Key Research and Development Program","doi-asserted-by":"publisher","award":["GuiKe AB24010082"],"award-info":[{"award-number":["GuiKe AB24010082"]}],"id":[{"id":"10.13039\/501100017691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iLIVER"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.iliver.2026.100236","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:49:36Z","timestamp":1777132176000},"page":"100236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of adjuvant transarterial chemoembolization in high-risk HCC after curative hepatectomy: a phase III RCT protocol"],"prefix":"10.1016","volume":"5","author":[{"given":"Chao-Man","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3387-2273","authenticated-orcid":false,"given":"Yi-He","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Qun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Feng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Meng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan-Jian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Bing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Sheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1494-6396","authenticated-orcid":false,"given":"Jian-Hong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.iliver.2026.100236_bib1","doi-asserted-by":"crossref","first-page":"18296","DOI":"10.18632\/oncotarget.15433","article-title":"Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: a real-world study","volume":"8","author":"Zhong","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.iliver.2026.100236_bib2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/SLA.0000000000000236","article-title":"Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma","volume":"260","author":"Zhong","year":"2014","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.iliver.2026.100236_bib3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/gutjnl-2014-308139","article-title":"Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours, or portal hypertension","volume":"64","author":"Zhong","year":"2015","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.iliver.2026.100236_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/bjs\/znab340","article-title":"Repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: retrospective multicentre study","volume":"109","author":"Zhong","year":"2021","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.iliver.2026.100236_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrac036","article-title":"Repeat hepatic resection versus percutaneous ablation for the treatment of recurrent hepatocellular carcinoma: meta-analysis","volume":"6","author":"Yuan","year":"2022","journal-title":"BJS Open"},{"issue":"4","key":"10.1016\/j.iliver.2026.100236_bib6","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.surg.2019.11.005","article-title":"Repeat hepatectomy for patients with early and late recurrence of hepatocellular carcinoma: a multicenter propensity score matching analysis","volume":"169","author":"Xing","year":"2021","journal-title":"Surgery"},{"issue":"3","key":"10.1016\/j.iliver.2026.100236_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.iliver.2024.100110","article-title":"Optimising postoperative surveillance for hepatocellular carcinoma: beyond histological predictors","volume":"3","author":"Xu","year":"2024","journal-title":"ILIVER"},{"issue":"2","key":"10.1016\/j.iliver.2026.100236_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.21037\/hbsn-21-288","article-title":"Predictors and long-term prognosis of early and late recurrence for patients undergoing hepatic resection of hepatocellular carcinoma: a large-scale multicenter study","volume":"12","author":"Yan","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"1","key":"10.1016\/j.iliver.2026.100236_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1742-1241.2011.02814.x","article-title":"Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review","volume":"66","author":"Zhong","year":"2012","journal-title":"Int J Clin Pract"},{"issue":"3","key":"10.1016\/j.iliver.2026.100236_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174222","article-title":"Timely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy","volume":"12","author":"Mo","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.iliver.2026.100236_bib11","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1136\/gutjnl-2019-320326","article-title":"Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis","volume":"69","author":"Teng","year":"2020","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.iliver.2026.100236_bib12","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/jgh.15783","article-title":"Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis","volume":"37","author":"Yuan","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.iliver.2026.100236_bib13","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00535-023-02018-2","article-title":"Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study","volume":"58","author":"Li","year":"2023","journal-title":"J Gastroenterol"},{"issue":"3","key":"10.1016\/j.iliver.2026.100236_bib14","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41591-023-02786-7","article-title":"Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.iliver.2026.100236_bib15","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000542954","article-title":"Treatment duration of adjuvant immune checkpoint inhibitors in hepatocellular carcinoma patients at high risk of recurrence after resection: a prospective, multicentric cohort study","volume":"14","author":"Su","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.iliver.2026.100236_bib16","article-title":"Tertiary lymphoid structures in HCC: influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy","author":"Su","year":"2025","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.iliver.2026.100236_bib17","first-page":"779","article-title":"China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 edition)","volume":"14","author":"Zhou","year":"2025","journal-title":"Liver Cancer"},{"issue":"10","key":"10.1016\/j.iliver.2026.100236_bib18","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1872-034X.2010.00710.x","article-title":"Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: a meta-analysis","volume":"40","author":"Zhong","year":"2010","journal-title":"Hepatol Res"},{"issue":"4","key":"10.1016\/j.iliver.2026.100236_bib19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.amjsurg.2018.07.054","article-title":"Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma involving microvascular invasion","volume":"217","author":"Qi","year":"2019","journal-title":"Am J Surg"},{"issue":"1","key":"10.1016\/j.iliver.2026.100236_bib20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/HEP.0000000000001269","article-title":"Critical update: AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"82","author":"Taddei","year":"2025","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.iliver.2026.100236_bib21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","author":"Sangro","year":"2025","journal-title":"J Hepatol"},{"issue":"Suppl 5","key":"10.1016\/j.iliver.2026.100236_bib22","doi-asserted-by":"crossref","first-page":"v59","DOI":"10.1093\/annonc\/mdq166","article-title":"Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Jelic","year":"2010","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.iliver.2026.100236_bib23","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.iliver.2026.100236_bib24","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/gutjnl-2023-331695","article-title":"British society of gastroenterology guidelines for the management of hepatocellular carcinoma in adults","volume":"73","author":"Suddle","year":"2024","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.iliver.2026.100236_bib25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.iliver.2026.100236_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17998\/jlc.2022.11.07","article-title":"2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma","volume":"23","year":"2023","journal-title":"J Liver Cancer"},{"issue":"10","key":"10.1016\/j.iliver.2026.100236_bib27","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/hepr.13411","article-title":"Clinical practice guidelines for hepatocellular carcinoma: the Japan society of hepatology 2017 (4th JSH-HCC guidelines) 2019 update","volume":"49","author":"Kokudo","year":"2019","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.iliver.2026.100236_bib28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jceh.2019.09.007","article-title":"2019 update of Indian national association for study of the liver consensus on prevention, diagnosis, and management of hepatocellular carcinoma in India: the Puri II recommendations","volume":"10","author":"Kumar","year":"2020","journal-title":"J Clin Exp Hepatol"},{"issue":"5","key":"10.1016\/j.iliver.2026.100236_bib29","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000530495","article-title":"Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition)","volume":"12","author":"Zhou","year":"2023","journal-title":"Liver Cancer"},{"issue":"9","key":"10.1016\/j.iliver.2026.100236_bib30","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1158\/1078-0432.CCR-17-2899","article-title":"Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.iliver.2026.100236_bib31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40880-018-0331-y","article-title":"Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety","volume":"38","author":"Wei","year":"2018","journal-title":"Cancer Commun"},{"issue":"3","key":"10.1016\/j.iliver.2026.100236_bib32","first-page":"281","article-title":"Efficacy of transcatheter arterial chemoembolization following radical resection in cases of intermediate to advanced hepatocellular carcinoma with microvascular invasion: a multicenter cohort study","volume":"17","author":"Li","year":"2025","journal-title":"Chin J Oncol Prev Treat"},{"issue":"5","key":"10.1016\/j.iliver.2026.100236_bib33","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1097\/HEP.0000000000001233","article-title":"Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: a randomized, open-label, phase 3 trial","volume":"82","author":"Ma","year":"2025","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.iliver.2026.100236_bib34","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/hepr.14219","article-title":"Adjuvant transarterial chemoembolization after truly curative resection does not improve survival of patients with hepatocellular carcinoma at high risk of recurrence: a target trial emulation study","volume":"55","author":"Su","year":"2025","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.iliver.2026.100236_bib35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13063-023-07742-x","article-title":"Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial","volume":"25","author":"Pan","year":"2024","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.iliver.2026.100236_bib36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.iliver.2026.100236_bib37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"}],"container-title":["iLIVER"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772947826000204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772947826000204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T20:43:07Z","timestamp":1783197787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772947826000204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2772947826000204"],"URL":"https:\/\/doi.org\/10.1016\/j.iliver.2026.100236","relation":{},"ISSN":["2772-9478"],"issn-type":[{"value":"2772-9478","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of adjuvant transarterial chemoembolization in high-risk HCC after curative hepatectomy: a phase III RCT protocol","name":"articletitle","label":"Article Title"},{"value":"iLIVER","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iliver.2026.100236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of Tsinghua University Press.","name":"copyright","label":"Copyright"}],"article-number":"100236"}}